FDA approves first treatment for pediatric functional constipation

FDA has approved Linzess (linaclotide) capsules to treat functional constipation in pediatric patients 6 to 17 years of age. Linzess is the first treatment for pediatric functional constipation. The recommended dosage in pediatric patients 6 to 17 years is 72 mcg orally once daily.

Source: FDA Center for Drug Evaluation and Research - What's New - June 12, 2023 Category: Drugs & Pharmacology Authors: FDA Source Type: news